Cargando…
Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States
Hepatitis C virus is a serious infection causing cirrhosis, liver cancer, and death. The recent development of direct-acting antivirals has dramatically improved tolerability of treatment and rates of cure. However, the high price of these medications has often limited access to care and resulted in...
Autores principales: | Rosenthal, Elana S., Graham, Camilla S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867525/ https://www.ncbi.nlm.nih.gov/pubmed/27186235 http://dx.doi.org/10.1186/s13027-016-0071-z |
Ejemplares similares
-
Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus
por: van de Ven, Nikolien, et al.
Publicado: (2015) -
Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection
por: Salama, Iman Ibrahim, et al.
Publicado: (2022) -
Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries
por: Barber, Melissa J., et al.
Publicado: (2020) -
Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals
por: Gountas, Ilias, et al.
Publicado: (2019) -
Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals
por: Lee, Hye Won, et al.
Publicado: (2020)